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Multiple sclerosis (MS) is characterized by a wide interpatient clinical variability and available biomarkers of disease severity still
have suboptimal reliability. We aimed to assess immunological and MRI-derived measures of brain tissue damage in patients with
different motor impairment degrees, for in vivo investigating the pathogenesis of MS-related disability. Twenty-two benign (B), 26
secondary progressive (SP), and 11 early, nondisabled relapsing-remitting (RR)MS patients and 37 healthy controls (HC) underwent
conventional and diffusion tensor brainMRI and, as regardsMS patients, immunophenotypic and functional analysis of stimulated
peripheral blood mononuclear cells (PBMC). Corticospinal tract (CST) fractional anisotropy and grey matter volume were lower
and CST diffusivity was higher in SPMS compared to RRMS and BMS patients. CD14+IL6+ and CD4+IL25+ cell percentages
were higher in BMS than in SPMS patients. A multivariable model having EDSS as the dependent variable retained the following
independent predictors: grey matter volume, CD14+IL6+ and CD4+IL25+ cell percentages. In patients without motor impairment
after long-lasting MS, the grey matter and CST damage degree seem to remain as low as in the earlier disease stages and an
immunological pattern suggestive of balanced pro- and anti-inflammatory activity is observed. MRI-derived and immunological
measures might be used as complementary biomarkers of MS severity.
1. Introduction
A hallmark of multiple sclerosis (MS) is the wide intra-
and interpatient phenotypic variability. Since the earliest
descriptions of MS, it has been reported that the commonest
clinical form, that is, the relapsing-remitting (RR) one, does
often evolve into a disabling, secondary progressive (SP) stage
within 15 years [1]. Conversely, a nondisabling course, named
benignMS (BMS), can occur in patients with minimal motor
impairment 15 years after the onset, even if they experience
clinical relapses. Nonetheless, the actual existence of “truly”
BMS is still a matter of debate, since several reports describe
BMS patients accumulating disability and even converting to
SP in a later phase of the disease [2, 3]. Therefore, different
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aspects ofMS, including cognitive functioning,MRI features,
and immunological markers, have been extensively inves-
tigated [4–6] with the aim to achieve a better knowledge
of BMS versus SPMS and to identify possible biomarkers
associated with a favorable disease course.
During the last 20 years, MRI techniques have broadened
our knowledge on the mechanisms underlying disability
accrual inMS [7, 8].More recently, severalMRI-based studies
reported that a regional quantification of damage in clinically
eloquent areas has a better correlation with disability than
global measures [9, 10]. The analysis of immunological data
is also of outmost importance to understand the pathogenesis
of different MS clinical forms. No reliable laboratory markers
of MS severity have been found yet, but several studies
investigating cytokine levels and lymphocyte subsets from
the peripheral blood of MS patients [11, 12] have shed some
light on the balance between tissue damage and repair and
on the different recruitment of the various components
of the immune system according to the disease stage and
phenotype.
Against this background, this cross-sectional study was
conducted to obtain both laboratory parameters reflecting
immune system functioning and MRI-derived markers of
tissue damage from patients with BMS, SPMS, and early
RRMS. The dual aim was to better investigate the potential
of different biomarkers of MS severity and to increase our
knowledge about the mechanisms related to the aforemen-
tioned clinical disease heterogeneity.
2. Material and Methods
2.1. Subjects. Patients with establishedMS [13] were recruited
from the population attending the MS Center of the Fon-
dazione Don Gnocchi. All patients had to be relapse- and
steroid-free for at least 3 months. Complete neurological
examination with expanded disability status scale (EDSS)
score rating [14] was performed in all patients by a single
neurologist. MS course had to be benign (disease duration
≥ 15 years, EDSS ≤ 3.0), early, nondisabling RR (disease
duration ≤ 3 years, EDSS score ≤ 3.0) or SP [15]. Patients had
to be free from acute or chronic infections. Healthy controls
(HC) from a previous study [16] (group 1 HC) were used to
prepare a corticospinal tract (CST) tractographic atlas. Other
subjects with no history of neurological, cardiovascular, or
metabolic disorders and a normal neurological examination,
age-matched with MS patients (group 2 HC), were recruited
as controls for the MRI evaluations. The study was approved
by the local Ethics Committee and a written informed
consent was obtained from all subjects prior to study entry.
2.2. MRI Acquisition. Brain MRI was acquired from all
subjects using a 1.5 Tesla scanner (Siemens Magnetom
Avanto, Erlangen, Germany), equipped with a 12-channel
head coil. The following sequences were obtained: (1) dual-
echo turbo spin echo (repetition time (TR) = 2650ms, echo
time (TE) = 28/113ms; echo train length = 5; flip angle = 150∘,
50 axial slices with a matrix size = 256 × 256, interpolated to
512 × 512, field of view (FOV) = 250 × 250mm, slice thickness
2.5mm); (2) 3D T1-weighted magnetization-prepared rapid
acquisition gradient echo (MP-RAGE) (TR/TE/inversion
time = 1900/3.37/1100ms, flip angle = 15∘, 176 axial slices,
voxel size = 1 × 1 × 1mm, 192 × 256 matrix); (3)
diffusion-weighted single shot spin-echo sequence (TR/TE
= 7100/94ms, 50 axial slices, 128 × 96 matrix, FOV = 320
× 240mm, slice thickness = 2.5mm). The DTI protocol
included two runs, each with 12 noncollinear diffusion
gradients (𝑏 = 900 s/mm2) and 1 nondiffusion-weighted (𝑏 =
0 s/mm2); (4) postcontrast (gadoteridol 0.1mmol/Kg) T1-
weighted (TR/TE = 650/44ms, 44 axial slices, slice thickness
3mm, 256 × 256 matrix, FOV = 250 × 250mm). All slices
were positioned to run parallel to a line that joins the most
inferior-anterior and inferior-posterior parts of the corpus
callosum.
2.3. MRI Data Analysis and Postprocessing. MS lesions were
identified on proton density-weighted scans, using the cor-
responding T2-weighted images to increase confidence in
lesion identification. Lesion segmentation and brain lesion
volume (LV) computation were performed using the Jim
software (Jim 5.0, Xinapse System, Leicester, UK). The pres-
ence and number of enhancing lesions on postcontrast T1-
weighted images were also assessed.
3D T1-weighted images were processed with the cross-
sectional version of the Structural Image Evaluation of
Normalized Atrophy software (SIENAX) [17], with a mask
image of the lesions (previously coregistered from T2
to T1 volume). The normalized volumes of grey matter
(NGMV), cortical grey matter (NCV), white matter
(WMV), and brain parenchyma (NBV) were measured.
Diffusion-weighted images were preprocessed using FSL
(http://www.fmrib.ox.ac.uk/fsl/), and then DT in every voxel
and the DT-derived maps, that is, mean diffusivity (MD) and
fractional anisotropy (FA), were estimated using Diffusion
Toolkit software version 0.4.2 (http://www.trackvis.org/),
following a process described elsewhere [16]. MS lesions
(previously coregistered to the 𝑏 = 0 volume) were masked
out from the DT-derived maps. We created a left and right
CST probabilistic atlas, as described in the literature [18],
using TrackVis v0.4.3 (http://www.trackvis.org/) for the CST
tractography of group 1 HC. With the probabilistic atlas
and the lesion-masked DT-derived maps of every subject,
the mean FA and MD of the normal-appearing CST were
computed forMS patients and group 2HC, using themethod
described in the literature [19].
2.4. Immunology. Blood samples were obtained from MS
patients within 24 hours from MRI scan acquisition. Data
from an historical control group of 40 age- and sex-matched
healthy subjects were used to provide normal reference
values. In order to identify immunological biomarkers, the
functional differentiation of Myelin Basic Protein- (MBP-)
stimulated CD4+ and CD14+ cell subsets was assessed using
immunofluorescent staining protocol and flow-cytometry
analysis [20]. The following immune cell subsets were
analysed and categorised as markers of (a) proinflam-
matory response: CD4+IFN𝛾+, CD4+IL17+, CD14+IL6+,
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Table 1: Demographic and clinical characteristics of the study subjects.
HClab HC All MS BMS RRMS SPMS
Number 40 37 59 22 11 26
Mean age (SD) (years) 44.2 (10.7) 45.7 (14.4) 46.2 (9.8) 46.5 (7.2) 37.5 (9.5) 49.6 (9.9)
Men/women 12/28 15/22 21/38 9/13 5/6 7/19
Mean disease duration (SD) (years) — 18.0 (9.6) 20.9 (4.8) 2.1 (0.7) 22.4 (7.6)
Median EDSS (range) — 3.0 (0.0–7.5) 1.5 (0.0–3.0) 1.5 (0.0–3.0) 6.0 (4.0–7.5)
HClab: historical healthy controls for immunology; HC: healthy controls recruited for magnetic resonance measures; MS: multiple sclerosis; BMS: benign MS;
relapsing-remitting MS; secondary progressive MS.
Table 2: Conventional and DT MRI findings from HC and all MS
patients.
HC (𝑛 = 37) All MS (𝑛 = 59) HC versus MS
LV — 16.5 (15.5) —
NBV 1531.3 (78.1) 1462.2 (91.2) <0.001
NCV 624.0 (48.4) 577.8 (74.6) <0.0001
NGMV 790.6 (55.2) 722.9 (95.4) <0.0001
NWMV 737.6 (36.7) 739.2 (39.2) <0.001
Left CST FA 0.515 (0.038) 0.490 (0.050) 0.016
Left CST MD 0.727 (0.029) 0.736 (0.051) ns
Right CST FA 0.496 (0.024) 0.459 (0.039) <0.001
Right CST MD 0.749 (0.026) 0.762 (0.053) ns
Data are reported as mean (standard deviations). 𝑃 values from group
comparisons (𝑡-test) are reported. Lesion and tissue volumes are expressed
in cc, MD is expressed in 10−3mm2 s−1, and FA is a dimensionless index.
LV: total brain lesion volume; NBV: normalized brain volume; NCV:
normalized cortical grey matter volume; NGMV: normalized grey matter
volume; NWMV: normalized white matter volume; CST: corticospinal tract;
MD: mean diffusivity; FA: fractional anisotropy; ns: not significant.
See the text for other abbreviations and statistical analysis details.
and CD14+IL12p35+ cells; (b) anti-inflammatory response:
CD4+IL13+, CD4+ IL25+, CD14+IL10+ and CD14+TGF-𝛽+
cells; (c) tissue repair: CD4+BDNF+ cells [20].
2.5. Statistical Analysis. Median and interquartile ranges
were used according to skewness evaluated by the Kolmog-
orov-Smirnov test. Univariate correlations between clinical
and paraclinical variables were assessed using the Spearman
correlation coefficient with Fisher’s Z transformation [21].
Paraclinical variables were normalized using the Blom’s
transformation [22] and compared by group using a gen-
eralized linear model (GLM) analysis of variance model
corrected for age, gender, and therapy as dummy variables.
To account for unequal number of observations, multiple
comparisons between groups were performed by the Tukey-
Kramer [23] method. Least squares means and 95% confi-
dence limits were obtained by retrotransformation.
To investigate which MRI and immunological variables
were independent predictors of patients’ EDSS, a variable
selection method based on the GLM approach was used.
To assess whether immunological variables were signif-
icantly different between treated and untreated patients, we
used GLM analysis of variance corrected for age and gender.
All statistical tests were two-tailed and Bonferroni correc-
tion for multiple comparisons was applied to all univariate
tests.
Statistical evaluations were performed using SAS statisti-
cal software v. 9.2.
3. Results
Fifty-nine patients (22 with BMS, 11 with RRMS and 26 with
SPMS) and 37 HC were studied (Table 1). No differences
between MS patients and HC were found for gender (𝜒2 =
1.59, 𝑃 = 0.45) and age (𝑃 = 0.74). At post hoc comparisons,
an age difference (𝑃 = 0.024) was found between RRMS
and SPMS patients. No significant difference between SPMS
and BMS patients was found for age and disease duration,
which was, for the inclusion criteria, lower (𝑃 < 0.0001) for
RRMS patients. At the time of the study, 22 (37%) patients
were being treated with disease-modifying drugs: 13 with
interferon 𝛽-1a, 1 with interferon 𝛽-1b, 6 with glatiramer
acetate, and 2 with azathioprine. Disease phenotypes in these
patients were: BMS in 8 (36%), 6 treated with interferon 𝛽-
1a and 2 with glatiramer acetate; RRMS in 8 (73%), 5 treated
with interferon 𝛽-1a, 1 treated with interferon 𝛽-1b, 1 with
glatiramer acetate, and 1 with azathioprine; SPMS in 6 (23%),
2 treated with interferon 𝛽-1a, 3 with glatiramer acetate, and
1 with azathioprine.
3.1. MRI Findings. Contrast-enhancing lesions were found
in 1 BMS patient (4%), 4 RRMS patients (36%), and 15
SPMS patients (58%), that is, in a total of 20 patients
(34%) in the whole MS cohort. Tables 2 and 3 report the
values of MRI-derived measures in the whole cohort and
in the different subjects’ subgroups. All MRI variables were
normally distributed within each subgroup.
LV was the highest in SPMS patients, but there were no
significant differences between patients’ subgroups. All brain
tissue volumes were lower in MS patients than in HC. All
brain tissue volumes were not statistically different between
BMS and RRMS, while NBV andNGMVwere lower in SPMS
than in BMS and RRMS patients.
In both HC and MS patients, a difference (𝑃 < 0.0001)
was found between left and right CST FA and MD values,
with FAbeing lower andMDhigher in the right tract. Average
left and right CST FA were lower in MS patients than in HC
and heterogeneous between patient subgroups. At post hoc
comparisons, SPMS patients had lower FA and higher MD
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Table 3: Conventional and DT MRI findings from patients with different MS phenotypes.
BMS RRMS SPMS BMS versus
RRMS
BMS versus
SPMS
SPMS versus
RRMSLS mean 95% CL LS mean 95% CL LS mean 95% CL
LV 10.6 4.5 16.6 6.8 −2.3 16.0 28.4 21.9 35.0 ns ns ns
NBV 1483.3 1452.4 1514.2 1564.3 1517.3 1611.3 1386.1 1352.6 1419.6 ns 0.001 0.003
NCV 605.3 579.0 631.6 642.8 602.8 682.7 516.9 488.4 545.4 ns ns ns
NGMV 759.1 726.1 792.2 809.9 759.7 860.2 644.1 608.3 679.9 ns <0.001 0.0001
NWMV 724.1 706.6 741.6 754.3 727.7 781.0 742.0 723.0 761.0 ns ns ns
Left CST FA 0.505 0.486 0.524 0.536 0.506 0.565 0.455 0.434 0.476 ns <0.001 0.002
Left CST MD 0.720 0.698 0.742 0.713 0.680 0.746 0.765 0.741 0.789 ns <0.001 <0.0001
Right CST FA 0.473 0.458 0.488 0.496 0.473 0.518 0.432 0.416 0.448 ns <0.0001 <0.0001
Right CST MD 0.746 0.725 0.767 0.723 0.691 0.756 0.794 0.771 0.817 ns <0.0001 <0.0001
Data are reported as least squares (LS)means and 95% confidence limits (CL). Lesion and tissue volumes are expressed in cc,MD is expressed inmm2s−1×10−3,
and FA is a dimensionless index. Between-group comparison 𝑃 values were corrected with Tukey-Kramer and the following variables were taken as covariates:
therapy (dichotomic variable: yes/no), age, and gender.
LV: total brain lesion volume; NBV: normalized brain volume; NCV: normalized cortical greymatter volume; NGMV: normalized greymatter volume; NWMV:
normalized white matter volume; CST: corticospinal tract; MD: mean diffusivity; FA: fractional anisotropy; ns: not significant.
See the text for other abbreviations and statistical analysis details.
Table 4: Percentages of MBP-stimulated cytokine producing blood
cells from historical controls and all MS patients.
Cell type Historicalcontrols All MS
All MS versus
historical controls
CD4+IL17+ 0.0 (0-0) 0.04 (0–0.08) <0.0001
CD4+IFN𝛾+ 0.01 (0–0.08) 0.01 (0–0.03) ns
CD14+IL12p35+ 0.0 (0-1) 0.13 (0–2.01) ns
CD14+IL6+ 0.0 (0-1) 1.9 (0–5.5) ns
CD4+IL13+ 0.05 (0–0.1) 0.12 (0.01–0.16) 0.003
CD4+IL25+ 0.13 (0–0.15) 0.33 (0.1–0.5) <0.0001
CD14+IL10+ 12.0 (0.03–26.8) 12.1 (0.17–21.3) ns
CD14+TGF𝛽+ 0.0 (0-1) 1.65 (0–6.25) ns
CD4+BDNF+ 0.07 (0–0.43) 0.72 (0–2.8) <0.0001
Data are reported as median values (interquartile ranges).
𝑃 values from group comparisons (𝑡-test) are reported; ns: not significant.
values than both BMS and RRMS patients, but no differences
were found between the latter subgroups.
3.2. Immunological Findings. Cytokine expression was not
observed in cell cultures incubated with nonantigenic pep-
tides, according to published results (data not shown) [24].
Tables 4 and 5 report the values of individual cell subset
percentages in the study subjects.
Regarding markers of proinflammatory response,
CD4+IL17+ cell percentagewas the only one that significantly
increased in MS patients compared to the normal reference
values. CD14+IL6+ cells were higher in MS patients than
in the normal control group too, but the difference did
not reach statistical significance. However, the percentage
of CD14+IL6+ cells was higher in BMS than in SPMS
(𝑃 < 0.0001) and RRMS (𝑃 = 0.004) patients (Table 5).
Regarding anti-inflammatory markers, CD4+IL13+ and
CD4+IL25+ cell percentages were significantly increased in
MS patients compared to the normal reference values. The
analysis of between-patient group differences showed that
CD4+IL25+ cell percentagewas lower in SPMS than inRRMS
(𝑃 < 0.0001) and BMS patients (𝑃 < 0.0001) (Table 5).
CD4+BDNF+ cell percentage was significantly increased
in MS patients compared to the normal reference values, but
did not differ between MS phenotypes.
No cell subset percentages were significantly different
between treated and untreated patients (data not shown).
3.3. Clinical Correlations. Univariate correlations between
patients’ EDSS and paraclinical variables are reported in
Table 6. With the exception of WMV and left CST MD,
all MRI metrics showed a significant relationship with dis-
ability levels, with the highest being with NGMV. Higher
disability levels were associated with lower CD14+IL6+ and
CD4+IL25+ cell percentages, with the strongest correlation
being the one with CD4+IL25+.
The final multivariable model having EDSS as the depen-
dent variable retained the following independent predictors:
NGMV (beta = −0.01, SE = 0.003, 𝑃 < 0.0001), CD4+IL25+
cell percentage (beta = −3.5, SE = 1.29, 𝑃 = 0.01), and
CD14+IL6+ cell percentage (beta = −0.04, SE = 0.02, 𝑃 =
0.07) (global 𝑅2 = 0.57, intercept: beta = 14,5, SE = 1,89,
𝑃 < 0.0001).
4. Discussion
The identification of biomarkers of MS severity and a better
understanding of its pathogenesis remain issues of outmost
importance to improve our workup of the disease as regards
the search for novel treatment strategies and the assessment
of their efficacy. To the best of our knowledge, this is the
first in vivo study where MRI-derived and immunological
metrics have been investigated in combination to readdress
these aims.
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Table 5: Percentages of MBP-stimulated cytokine producing blood cells from patients with different MS phenotypes.
Cell type BMS RRMS SPMS
BMS versus
RRMS
BMS versus
SPMS
SPMS versus
RRMSLS mean 95% CL LS mean 95% CL LS mean 95% CL
CD4+IL17+ 0.07 −0.02 0.21 0.09 −0.07 0.24 0.12 0.02 0.23 ns ns ns
CD4+IFN𝛾+ 0.02 −0.14 0.17 0.16 −0.09 0.42 0.13 −0.08 0.34 ns ns ns
CD14+IL12p35+ 2.02 0.90 3.13 0.93 −0.80 2.65 1.17 −0.08 2.42 ns ns ns
CD14+IL6+ 15.24 10.53 19.96 1.72 −4.82 8.27 0.64 −4.03 5.32 0.004 <0.0001 ns
CD4+IL13+ 0.16 0.13 0.20 0.12 0.06 0.17 0.11 0.07 0.15 ns ns ns
CD4+IL25+ 0.48 0.40 0.56 0.60 0.48 0.72 0.18 0.08 0.27 ns <0.0001 <0.0001
CD14+IL10+ 13.14 4.78 21.50 11.80 −0.05 23.64 20.32 11.32 29.32 ns ns ns
CD14+TGF𝛽+ 2.02 −0.63 4.66 5.52 1.66 9.38 4.83 2.03 7.62 ns ns ns
CD4+BDNF+ 1.77 −2.31 5.84 9.76 2.81 16.71 0.61 −3.68 4.90 ns ns ns
Data are reported as least squares (LS) means and 95% confidence limits. Between-group comparison 𝑃 values were corrected with Tukey-Kramer and the
following variables were taken as covariates: therapy (dichotomic variable: yes/no), age, and gender; ns: not significant.
Table 6: Univariate correlations between patients’ EDSS, MRI-
derived, and immunological variables.
SCC 95% CL 𝑃 value
MRI metrics
LV 0.420 0.151 0.612 0.001
NCV −0.555 −0.709 −0.342 <0.0001
NGMV −0.593 −0.736 −0.391 <0.0001
NWMV 0.095 −0.168 0.344 ns
NBV −0.576 −0.724 −0.368 <0.0001
Left CST FA −0.401 −0.595 −0.156 0.0016
Left CST MD 0.310 0.054 0.524 ns
Right CST FA −0.469 −0.646 −0.236 0.0002
Right CST MD 0.365 0.114 0.567 0.0046
Cell percentages
CD4+IL17+ 0.062 −0.210 0.324 ns
CD4+IFN𝛾+ −0.172 −0.480 0.179 ns
CD14+IL12p35+ 0.054 −0.219 0.319 ns
CD14+IL6+ −0.418 −0.621 −0.153 0.0023
CD4+IL13+ −0.116 −0.386 0.175 ns
CD4+IL25+ −0.611 −0.760 −0.390 <0.0001
CD14+IL10+ 0.095 −0.184 0.358 ns
CD14+TGF𝛽+ 0.127 −0.155 0.388 ns
CD4+BDNF+ −0.057 −0.369 0.268 ns
Values are corrected for therapy (dichotomic variable), age and gender.
SCC: Spearman rank correlation coefficients; CL: confidence limits; LV:
total brain lesion volume; NBV: normalized brain volume; NCV: normalized
cortical greymatter volume; NGMV: normalized greymatter volume;WMV:
normalized white matter volume; CST: corticospinal tract; MD: mean
diffusivity; FA: fractional anisotropy. See the text for other abbreviations and
statistical analysis details.
In our sample of patients with levels of disability ranging
from absent to severe motor impairment different clinical
phenotypes are represented, that is, RR, SP, and benign MS.
GM volumes were the lowest in SPMS, while there was no
significant difference between RRMS and BMS, although the
latter subgroup had a disease duration comparable to that of
SPMS. These findings indicate that GM volume is the MRI
parameter with the strongest ability to discriminate between
MS patients with high versus low levels of disability, inde-
pendently of the disease duration.The twomainmechanisms
implicated in the pathogenesis of GM damage are cortical
demyelination, resulting in lesions detectable with ad hoc
MRI sequences, and neurodegeneration. The latter feature,
reflected by measures of tissue atrophy, has been described
in all MS phenotypes [8, 25], including BMS. Indeed, our
study did not include cognitive assessment, which enables us
to detect the presence of “occult” disease-related disability in
about one-third of BMS patients [26]. Despite this limitation,
leading to a possible overestimation of the “benignity” of
this subgroup, measures of GM damage did not significantly
differ between BMS and RRMS patients with a sixfold shorter
disease duration.This indicates that GM pathology, although
present, is much less severe and destructive in BMS, leading
to a lower disability and a slower progression of the disease.
As a consequence, reparative mechanisms might have the
possibility to act more effectively and limit the clinical impact
of tissue damage. A complementary explanation for the
milder disease course shown by BMS might be the different
topographical distribution of brain damage, with relative
sparing of clinically eloquent areas [4, 27, 28]. Against this
background, considering that the definition of BMS relies
on EDSS scoring, which is mainly determined by motor
disability, the comparison of CST-related measures between
BMS and the other phenotypes is of particular interest. CST
FA was altered in MS with respect to healthy controls, and
SPMS patients showed a more severe CST involvement than
BMS and RRMS. CST FA and MD also correlated with the
level of disability, as previously reported [29]. Once again,
BMS did not differ from early RRMS in any of thesemeasures
of CST damage. Considering that FA is mainly related to
axonal damage, these findings strengthen the hypothesis that
neurodegeneration in BMS is less destructive or occur more
slowly, thus allowing patients to benefit from reparative or
compensatory processes. In contrast with a previous study
[30], reporting no difference between BMS and HC in CST
FA, our BMS cohort had a significantly lower CST FA than
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HC (data not shown). One possible explanation is that
BMS patients belonging to that study had a slightly shorter
disease duration and cognitive impairment was an exclusion
criterion, whereas our patients were not cognitively assessed,
thereby allowing for the inclusion of less “benign” cases.
Consistently with the results of between-group comparisons,
the strongest correlation with patients’ EDSS scores was
achieved by NGMV values, but there was also a moderate
relationship with DT-derived measures of CST integrity.
Immunological data can be viewed as complementary to
MRI, because they give information on the balance between
inflammatory/anti-inflammatory processes and repairmech-
anisms.The cytokine network is very complex, and very often
the production/inhibition of some elements is strictly inter-
twined with many other components of the immune system.
To further complicate the picture, some elements, such as
TGF𝛽, can play a dual role, stimulating the production of
Th17 proinflammatory cells and cytokines (IL17) and, on the
other hand, protecting against autoimmune diseases through
tolerance induction. In addition, more than one-third of our
patients were being treated with disease-modifying therapies,
which have a great impact on several components of the
immune system [31]. This, together with the cross-sectional
and observational nature of the study, does not allow us to
draw any conclusions on the possible pathogenetic roles of
the cytokine analyzed.
We observed an increase of CD4+IL17+ cells in all MS
subtypes, confirming published data on their role in MS
pathogenesis in different disease stages [11]. The presence of
an important inflammatory component in SPMS, in which
neurodegeneration is thought to prevail [32], is confirmed by
the relatively high percentage of patients showing contrast-
enhancing MRI lesions. This result is similar to the high
percentage of activeMRI (53%) found in a previous study [33]
of 60 untreated SPMS patients and might be explained by the
low number of treated SPMS subjects (8 of 26) in our sample.
Indeed, interferon-beta trials showed that treatment was
effective in SPMS only when relapses were still superimposed
to disability progression [34], confirming that a variable
balance between inflammation and neurodegeneration can
be present in patients with this disease phenotype and that
both these components have an impact on disability accrual.
CD14+IL6+ cell percentage was also higher in MS
patients than in HC, although the difference did not reach
statistical significance. This finding is consistent with the
elevated levels of CD4+IL17+, considering that IL6 is respon-
sible for the amplification of the inflammatory response
through several mechanisms including Th17 proliferation
and recruitment. Interestingly, CD14+IL6+ cells were sig-
nificantly higher in BMS than in RRMS and SPMS. On
the other hand, recent data [35] indicate that IL6-driven
inflammation is evident in progressive MS and in motor
neuron disorders, which are both characterised by a dis-
abling course. An explanation for our findings might be
that the inflammatory response detected in BMS may, to
some extent, exert beneficial effects for tissue preservation
and be promoted to counterbalance tissue damage. Some
authors have indeed speculated on the possible positive role
of inflammation in MS, hypothesizing that inflammatory
reactionsmight promote repair and remyelination and confer
neuroprotection [36, 37]. In SPMS, the inflammatory pattern
seems to be more different than in the earlier stages of the
disease, since in the periphery there is a predominance ofTh2,
anti-inflammatory cells [12] and inflammation is thought to
be mainly sustained by a humoral component sequestered
inside the CNS [38, 39].
Anti-inflammatory cytokine-expressing lymphocyte lev-
els were elevated in MS patients compared to HC, possibly
and at least partially because of the immunomodulatory
effects of ongoing treatments. However, it is conceivable that
the inflammatory reaction associatedwithMS evokes an anti-
inflammatory, Th2-driven response that is maintained over
the course of the disease. It is worth noting that CD4+IL25+
cell percentage was significantly lower in SPMS than in
both BMS and RRMS patients. In addition, CD4+IL25+ cell
percentage was not significantly different between HC and
SPMS. This finding might be explained taking into con-
sideration the aforementioned compartmentalized humoral
immune response described in SPMS patients, associated
with a less pronounced involvement of peripheral immune
system. It is worth noting, however, that low levels of
CD4+IL25+ cells were overall associated with increasing
patients’ disability and with MRI features suggestive of
pronounced tissue damage (i.e., more severe brain atrophy
and CST abnormalities), indicating that a decrease of anti-
inflammatory response could indeed be responsible for a less
effective disease control. At any rate, one should always bear
in mind the difficulties to interpret immunological findings
obtained in vivo fromperipheral blood samples, which can be
influenced by biological factors independent of MS course.
The results of the multivariable analysis are consistent
with findings from group comparisons between patients with
different MS phenotypes and indicate that increasing EDSS
scores are explained by more severe GM damage and by
a decrease of both proinflammatory and anti-inflammatory
cytokine-producing lymphocytes in the peripheral blood.
5. Conclusions
Both MRI and immunological parameters were retained in
a multivariable model able to predict patients’ locomotor
disability on a cross-sectional basis. Given the intrinsic vari-
ability of immunological and MRI biomarkers, however, it
could be worth assessing them in an independent population
to confirm our results. In addition, this calls for longitudinal
studies aimed at evaluating whether a combination of these
metrics could enable us to early identify MS patients with a
favourable medium- to long-term prognosis.
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